by John Conrad | Jan 8, 2025 | Grants, NewsBrief
In partnership with G2G Consulting, we are please to provide the January 2025 Grants report, showcasing 196 non-dilutive government funding opportunities across diverse biomedical and life sciences sectors. The comprehensive report underscores significant funding...
by John Conrad | Dec 19, 2024 | Member News
Chicago-based Xentria advances Illinois’ position in life sciences innovation through strategic academic partnership* Illinois’ biotechnology sector continues to demonstrate its growing prominence with Xentria, Inc., a Chicago-based clinical-stage...
by John Conrad | Dec 18, 2024 | Capital Pulse
Flow Medical, a startup spun out of UChicago Medicine, has secured $5 million in seed funding, with UCM Ventures making its inaugural investment in the company. The startup, founded by three University of Chicago faculty members, is developing a specialized catheter...
by John Conrad | Dec 18, 2024 | iBIO in the News
iBIO President & CEO John Conrad recently had the pleasure of chatting with Kyle LaHucik to discuss the exciting developments in our biotech ecosystem. Many of you may have already seen his excellent article published yesterday in Endpoints News, which provides a...
by John Conrad | Dec 18, 2024 | iBIO News
As Illinois’ life sciences industry continues its remarkable growth trajectory, iBIO President and CEO John Conrad and iBIO Board Chair Ken Johnson, Senior Vice President of Global Development and Medical Affairs at Xeris Pharmaceuticals, sat down to discuss the...
by John Conrad | Dec 12, 2024 | Member News, NewsBrief
In a significant move addressing one of healthcare’s most pressing challenges, Meitheal Pharmaceuticals has secured exclusive U.S. commercial rights to XENLETA® (lefamulin acetate). The timing couldn’t be more critical: between now and 2050, antibiotic...
by John Conrad | Dec 3, 2024 | Member News
COUR Pharmaceuticals has secured a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize its tolerogenic nanoparticle treatments for autoimmune conditions. The partnership, announced via press release...
by John Conrad | Dec 2, 2024 | iBIO News
The newly released TECONOMY/BIO report, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions,” paints an impressive picture of Illinois’ life sciences industry. The data reveals an industry that’s not just...
by John Conrad | Dec 2, 2024 | iBIO News
The pharmaceutical industry faces a pivotal moment as political shifts introduce new dimensions of uncertainty into our operating environment. The recent election outcomes and potential leadership changes at key health agencies are reshaping the landscape for...
by John Conrad | Nov 14, 2024 | iBIO News
In a significant move to enhance science education across Illinois, the Illinois Biotechnology Innovation Organization (iBIO) has launched its innovative “LabShare” program. This groundbreaking program connects surplus laboratory equipment from iBIO member...